Helen S. Kim

Managing Director, Vida Ventures

Helen S. Kim brings more than 28 years of biotechnology leadership experience to the Board of Directors at A2 Bio. She currently serves as managing director of Vida Ventures and before that was a partner at The Column Group, a science-driven venture capital firm. Previously, Helen served as executive vice president of business development at Kite Pharma (acquired by Gilead) where she led all business and corporate development initiatives. Helen also served as strategic advisor of NGM Biopharmaceuticals, Inc. from 2012 to 2014, as well as chief business officer from 2009 to 2012. Prior that, she was the president and chief executive officer of Kosan Biosciences where she restructured and repositioned the company prior to its sale to Bristol-Myers Squibb in 2008. Helen is also a board member of Assembly Biosciences, Applied Molecular Transport, Exicure, Inc., Neogene, and PACT.